Publications by authors named "David A Parks"

Claim this Profile
E
Evaluating the interference potential of minerals in infrared absorbance-based quantification of respirable crystalline silica in mine dusts.
David A Parks, Seth A Finley, Priscilla M Tjandra, Leslie L Baker, Allegra Yeley

J Occup Environ Hyg· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Applying Finite Mixture Models to Quantify Respirable Dust Mass in Coal and Metal-Nonmetal Mines Using Fourier Transform Infrared Spectroscopy.
Andrew T Weakley, David A Parks, Arthur L Miller

Appl Spectrosc· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reducing Dust and Respirable Crystalline Silica Near Conveyors Using a Hybrid Dust Control System.
David A Parks, Grant W King, B David Koski, Greg S Bierie, Carl B Sunderman

Min Metall Explor· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of a non-dispersive infrared spectrometer for quantifying organic and elemental carbon in diesel particulate matter.
David A Parks, Yongli Zhao, Peter R Griffiths, Arthur L Miller

Aerosol Sci Technol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantifying elemental and organic carbon in diesel particulate matter by mid-infrared spectrometry.
David A Parks, Peter R Griffiths, Andrew T Weakley, Arthur L Miller

Aerosol Sci Technol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiation tolerance of piezoelectric bulk single-crystal aluminum nitride.
David A Parks, Bernhard R Tittmann

IEEE Trans Ultrason Ferroelectr Freq Control· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Steady-state amprenavir, tenofovir, and emtricitabine pharmacokinetics before and after reducing ritonavir boosting of a fosamprenavir/tenofovir/emtricitabine regimen from 200 mg to 100 mg once daily (TELEX II).
David A Parks, H Clay Jennings, Christopher Taylor, Gary E Pakes, Edward P Acosta

HIV Clin Trials· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of once-daily tenofovir, emtricitabine, ritonavir and fosamprenavir in HIV-infected subjects.
David A Parks, Harold C Jennings, Christopher W Taylor, Edward P Acosta

AIDS· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis